FDA Approves ORKAMBI(TM) (lumacaftor/ivacaftor) to treat underlying cause of CF
Vertex announced the FDA approved ORKAMBI™ (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test. July 02, 2015